137 related articles for article (PubMed ID: 34847435)
1. A multivalent Ara-C-prodrug nanoconjugate achieves selective ablation of leukemic cells in an acute myeloid leukemia mouse model.
Pallarès V; Unzueta U; Falgàs A; Aviñó A; Núñez Y; García-León A; Sánchez-García L; Serna N; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Cedó L; Eritja R; Villaverde A; Vázquez E; Casanova I; Mangues R
Biomaterials; 2022 Jan; 280():121258. PubMed ID: 34847435
[TBL] [Abstract][Full Text] [Related]
2. An Auristatin nanoconjugate targeting CXCR4+ leukemic cells blocks acute myeloid leukemia dissemination.
Pallarès V; Unzueta U; Falgàs A; Sánchez-García L; Serna N; Gallardo A; Morris GA; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Hematol Oncol; 2020 Apr; 13(1):36. PubMed ID: 32295630
[TBL] [Abstract][Full Text] [Related]
3. Antineoplastic effect of a diphtheria toxin-based nanoparticle targeting acute myeloid leukemia cells overexpressing CXCR4.
Pallarès V; Núñez Y; Sánchez-García L; Falgàs A; Serna N; Unzueta U; Gallardo A; Alba-Castellón L; Álamo P; Sierra J; Villaverde A; Vázquez E; Casanova I; Mangues R
J Control Release; 2021 Jul; 335():117-129. PubMed ID: 34004204
[TBL] [Abstract][Full Text] [Related]
4. T22-PE24-H6 Nanotoxin Selectively Kills CXCR4-High Expressing AML Patient Cells In Vitro and Potently Blocks Dissemination In Vivo.
Núñez Y; Garcia-León A; Falgàs A; Serna N; Sánchez-García L; Garrido A; Sierra J; Gallardo A; Unzueta U; Vázquez E; Villaverde A; Mangues R; Casanova I
Pharmaceutics; 2023 Feb; 15(3):. PubMed ID: 36986589
[TBL] [Abstract][Full Text] [Related]
5. Specific Cytotoxic Effect of an Auristatin Nanoconjugate Towards CXCR4
Falgàs A; Pallarès V; Unzueta U; Núñez Y; Sierra J; Gallardo A; Alba-Castellón L; Mangues MA; Álamo P; Villaverde A; Vázquez E; Mangues R; Casanova I
Int J Nanomedicine; 2021; 16():1869-1888. PubMed ID: 33716502
[TBL] [Abstract][Full Text] [Related]
6. Expression of TFRC helps to improve the antineoplastic effect of Ara-C on AML cells through a targeted delivery carrier.
Wu X; Jiao Z; Zhang J; Li F; Li Y
J Nanobiotechnology; 2023 Apr; 21(1):126. PubMed ID: 37041636
[TBL] [Abstract][Full Text] [Related]
7. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
8. Selective delivery of T22-PE24-H6 to CXCR4
Falgàs A; Pallarès V; Serna N; Sánchez-García L; Sierra J; Gallardo A; Alba-Castellón L; Álamo P; Unzueta U; Villaverde A; Vázquez E; Mangues R; Casanova I
Theranostics; 2020; 10(12):5169-5180. PubMed ID: 32373205
[No Abstract] [Full Text] [Related]
9. Selective depletion of metastatic stem cells as therapy for human colorectal cancer.
Céspedes MV; Unzueta U; Aviñó A; Gallardo A; Álamo P; Sala R; Sánchez-Chardi A; Casanova I; Mangues MA; Lopez-Pousa A; Eritja R; Villaverde A; Vázquez E; Mangues R
EMBO Mol Med; 2018 Oct; 10(10):. PubMed ID: 30190334
[TBL] [Abstract][Full Text] [Related]
10. Rational engineering of a human GFP-like protein scaffold for humanized targeted nanomedicines.
Álamo P; Cedano J; Conchillo-Sole O; Cano-Garrido O; Alba-Castellon L; Serna N; Aviñó A; Carrasco-Diaz LM; Sánchez-Chardi A; Martinez-Torró C; Gallardo A; Cano M; Eritja R; Villaverde A; Mangues R; Vazquez E; Unzueta U
Acta Biomater; 2021 Aug; 130():211-222. PubMed ID: 34116228
[TBL] [Abstract][Full Text] [Related]
11. Enhanced Anti-Leukemic Effects through Induction of Immunomodulating Microenvironment by Blocking CXCR4 and PD-L1 in an AML Mouse Model.
Hwang HS; Han AR; Lee JY; Park GS; Min WS; Kim HJ
Immunol Invest; 2019 Jan; 48(1):96-105. PubMed ID: 30204524
[TBL] [Abstract][Full Text] [Related]
12. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia.
Schneider C; Oellerich T; Baldauf HM; Schwarz SM; Thomas D; Flick R; Bohnenberger H; Kaderali L; Stegmann L; Cremer A; Martin M; Lohmeyer J; Michaelis M; Hornung V; Schliemann C; Berdel WE; Hartmann W; Wardelmann E; Comoglio F; Hansmann ML; Yakunin AF; Geisslinger G; Ströbel P; Ferreirós N; Serve H; Keppler OT; Cinatl J
Nat Med; 2017 Feb; 23(2):250-255. PubMed ID: 27991919
[TBL] [Abstract][Full Text] [Related]
13. Cellular intrinsic mechanism affecting the outcome of AML treated with Ara-C in a syngeneic mouse model.
Zhao W; Wei L; Tan D; Su G; Zheng Y; He C; Mao ZJ; Singleton TP; Yin B
PLoS One; 2014; 9(10):e109198. PubMed ID: 25314317
[TBL] [Abstract][Full Text] [Related]
14. A diphtheria toxin-based nanoparticle achieves specific cytotoxic effect on CXCR4
Falgàs A; Garcia-León A; Núñez Y; Serna N; Sánchez-Garcia L; Unzueta U; Voltà-Durán E; Aragó M; Álamo P; Alba-Castellón L; Sierra J; Gallardo A; Villaverde A; Vázquez E; Mangues R; Casanova I
Biomed Pharmacother; 2022 Jun; 150():112940. PubMed ID: 35421785
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of an anticancer drug with the FNIII14 peptide of fibronectin effectively overcomes cell adhesion-mediated drug resistance of acute myelogenous leukemia.
Matsunaga T; Fukai F; Miura S; Nakane Y; Owaki T; Kodama H; Tanaka M; Nagaya T; Takimoto R; Takayama T; Niitsu Y
Leukemia; 2008 Feb; 22(2):353-60. PubMed ID: 17972943
[TBL] [Abstract][Full Text] [Related]
16. RNA expression of genes involved in cytarabine metabolism and transport predicts cytarabine response in acute myeloid leukemia.
Abraham A; Varatharajan S; Karathedath S; Philip C; Lakshmi KM; Jayavelu AK; Mohanan E; Janet NB; Srivastava VM; Shaji RV; Zhang W; Abraham A; Viswabandya A; George B; Chandy M; Srivastava A; Mathews V; Balasubramanian P
Pharmacogenomics; 2015 Jul; 16(8):877-90. PubMed ID: 26083014
[TBL] [Abstract][Full Text] [Related]
17. Emodin and Its Combination with Cytarabine Induce Apoptosis in Resistant Acute Myeloid Leukemia Cells in Vitro and in Vivo.
Chen Y; Gan D; Huang Q; Luo X; Lin D; Hu J
Cell Physiol Biochem; 2018; 48(5):2061-2073. PubMed ID: 30099447
[TBL] [Abstract][Full Text] [Related]
18. A CXCR4-targeted nanocarrier achieves highly selective tumor uptake in diffuse large B-cell lymphoma mouse models.
Falgàs A; Pallarès V; Unzueta U; Céspedes MV; Arroyo-Solera I; Moreno MJ; Sierra J; Gallardo A; Mangues MA; Vázquez E; Villaverde A; Mangues R; Casanova I
Haematologica; 2020 Mar; 105(3):741-753. PubMed ID: 31248974
[TBL] [Abstract][Full Text] [Related]
19. Cancer-specific uptake of a liganded protein nanocarrier targeting aggressive CXCR4
Céspedes MV; Unzueta U; Álamo P; Gallardo A; Sala R; Casanova I; Pavón MA; Mangues MA; Trías M; López-Pousa A; Villaverde A; Vázquez E; Mangues R
Nanomedicine; 2016 Oct; 12(7):1987-1996. PubMed ID: 27085904
[TBL] [Abstract][Full Text] [Related]
20. Defective expression of deoxycytidine kinase in cytarabine-resistant acute myeloid leukemia cells.
Song JH; Kim SH; Kweon SH; Lee TH; Kim HJ; Kim HJ; Kim TS
Int J Oncol; 2009 Apr; 34(4):1165-71. PubMed ID: 19287976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
